TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions
Abstract
:1. Introduction
2. Results
2.1. Pan-TRK Immunohistochemistry
2.2. NTRK Fusion Analyses
2.3. TRK Expression and Clinicopathological Features
2.4. TRK Expression and Survival
3. Discussion
4. Materials and Methods
4.1. Samples
4.2. Immunohistochemistry
4.3. Microdissection
4.4. DNA Extraction
4.5. Detection of Merkel Cell Polyomavirus DNA
4.6. RNA Extraction
4.7. Real-Time RT-PCR
4.8. RNA-Based NGS
4.9. Fluorescence In Situ Hybridization
4.10. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Tetzlaff, M.T.; Harms, P.W. Danger is only skin deep: Aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma. Mod. Pathol. 2020, 33 (Suppl. 1), 42–55. [Google Scholar] [CrossRef]
- Becker, J.C.; Stang, A.; DeCaprio, J.A.; Cerroni, L.; Lebbé, C.; Veness, M.; Nghiem, P. Merkel cell carcinoma. Nat. Rev. Dis. Prim. 2017, 3, 17077. [Google Scholar] [CrossRef]
- Dika, E.; Pellegrini, C.; Lambertini, M.; Patrizi, A.; Ventura, A.; Baraldi, C.; Cardelli, L.; Mussi, M.; Fargnoli, M.C. Merkel cell carcinoma: An updated overview of clinico-pathological aspects, molecular genetics and therapy. Eur. J. Dermatol. 2021, 31, 691–701. [Google Scholar] [CrossRef]
- Youlden, D.R.; Soyer, H.P.; Youl, P.H.; Fritschi, L.; Baade, P.D. Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993–2010. JAMA Dermatol. 2014, 150, 864–872. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Soltani, A.M.; Allan, B.J.; Best, M.J.; Panthaki, Z.J.; Thaller, S.R. Merkel cell carcinoma of the hand and upper extremity: Current trends and outcomes. J. Plast. Reconstr. Aesthet. Surg. 2014, 67, e71–e77. [Google Scholar] [CrossRef] [PubMed]
- Zaar, O.; Gillstedt, M.; Lindelöf, B.; Wennberg-Larkö, A.M.; Paoli, J. Merkel cell carcinoma incidence is increasing in Sweden. J. Eur. Acad. Dermatol. Venereol. 2016, 30, 1708–1713. [Google Scholar] [CrossRef] [PubMed]
- Schadendorf, D.; Lebbé, C.; Zur Hausen, A.; Avril, M.F.; Hariharan, S.; Bharmal, M.; Becker, J.C. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur. J. Cancer 2017, 71, 53–69. [Google Scholar] [CrossRef] [Green Version]
- Knepper, T.C.; Montesion, M.; Russell, J.S.; Sokol, E.S.; Frampton, G.M.; Miller, V.A.; Albacker, L.A.; McLeod, H.L.; Eroglu, Z.; Khushalani, N.I.; et al. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin. Cancer Res. 2019, 25, 5961–5971. [Google Scholar] [CrossRef] [Green Version]
- Harms, K.L.; Healy, M.A.; Nghiem, P.; Sober, A.J.; Johnson, T.M.; Bichakjian, C.K.; Wong, S.L. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann. Surg. Oncol. 2016, 23, 3564–3571. [Google Scholar] [CrossRef] [PubMed]
- Rastrelli, M.; Del Fiore, P.; Russo, I.; Tartaglia, J.; Dal Monico, A.; Cappellesso, R.; Nicolè, L.; Piccin, L.; Fabozzi, A.; Biffoli, B.; et al. Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n = 143). Front. Oncol. 2021, 11, 737842. [Google Scholar] [CrossRef] [PubMed]
- Rastrelli, M.; Del Fiore, P.; Buja, A.; Vecchiato, A.; Rossi, C.R.; Chiarion Sileni, V.; Tropea, S.; Russano, F.; Zorzi, M.; Spina, R.; et al. A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. Front. Oncol. 2020, 10, 529. [Google Scholar] [CrossRef]
- Spada, F.; Bossi, P.; Caracò, C.; Sileni, V.C.; Dei Tos, A.P.; Fazio, N.; Grignani, G.; Maio, M.; Quaglino, P.; Queirolo, P.; et al. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: A Delphi panel. J. Immunother. Cancer 2022, 10, e004742. [Google Scholar] [CrossRef] [PubMed]
- Cocco, E.; Scaltriti, M.; Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 2018, 15, 731–747. [Google Scholar] [CrossRef] [PubMed]
- Knezevich, S.R.; McFadden, D.E.; Tao, W.; Lim, J.F.; Sorensen, P.H. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat. Genet. 1998, 18, 184–187. [Google Scholar] [CrossRef] [PubMed]
- Bourgeois, J.M.; Knezevich, S.R.; Mathers, J.A.; Sorensen, P.H. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am. J. Surg. Pathol. 2000, 24, 937–946. [Google Scholar] [CrossRef]
- Anderson, J.; Gibson, S.; Sebire, N.J. Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma. Histopathology 2006, 48, 748–753. [Google Scholar] [CrossRef]
- Vasudev, P.; Onuma, K. Secretory breast carcinoma: Unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch. Pathol. Lab. Med. 2011, 135, 1606–1610. [Google Scholar] [CrossRef] [Green Version]
- Skálová, A.; Vanecek, T.; Sima, R.; Laco, J.; Weinreb, I.; Perez-Ordonez, B.; Starek, I.; Geierova, M.; Simpson, R.H.; Passador-Santos, F.; et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: A hitherto undescribed salivary gland tumor entity. Am. J. Surg. Pathol. 2010, 34, 599–608. [Google Scholar] [CrossRef]
- Tognon, C.; Knezevich, S.R.; Huntsman, D.; Roskelley, C.D.; Melnyk, N.; Mathers, J.A.; Becker, L.; Carneiro, F.; MacPherson, N.; Horsman, D.; et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002, 2, 367–376. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Solomon, J.P.; Linkov, I.; Rosado, A.; Mullaney, K.; Rosen, E.Y.; Frosina, D.; Jungbluth, A.A.; Zehir, A.; Benayed, R.; Drilon, A.; et al. NTRK fusion detection across multiple assays and 33,997 cases: Diagnostic implications and pitfalls. Mod. Pathol. 2020, 33, 38–46. [Google Scholar] [CrossRef]
- Drilon, A.; Laetsch, T.W.; Kummar, S.; DuBois, S.G.; Lassen, U.N.; Demetri, G.D.; Nathenson, M.; Doebele, R.C.; Farago, A.F.; Pappo, A.S.; et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N. Engl. J. Med. 2018, 378, 731–739. [Google Scholar] [CrossRef] [PubMed]
- Liu, D.; Offin, M.; Harnicar, S.; Li, B.T.; Drilon, A. Entrectinib: An orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther. Clin. Risk Manag. 2018, 14, 1247–1252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Solomon, J.P.; Hechtman, J.F. Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Res. 2019, 79, 3163–3168. [Google Scholar] [CrossRef] [PubMed]
- Conde, E.; Hernandez, S.; Sanchez, E.; Regojo, R.M.; Camacho, C.; Alonso, M.; Martinez, R.; Lopez-Rios, F. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer. Arch. Pathol. Lab. Med. 2021, 145, 1031–1040. [Google Scholar] [CrossRef]
- Farago, A.F.; Taylor, M.S.; Doebele, R.C.; Zhu, V.W.; Kummar, S.; Spira, A.I.; Boyle, T.A.; Haura, E.B.; Arcila, M.E.; Benayed, R.; et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis. Oncol. 2018, 2018, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Sigal, D.S.; Bhangoo, M.S.; Hermel, J.A.; Pavlick, D.C.; Frampton, G.; Miller, V.A.; Ross, J.S.; Ali, S.M. Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors. Oncotarget 2018, 9, 35809–35812. [Google Scholar] [CrossRef] [Green Version]
- Fernandez-Cuesta, L.; Peifer, M.; Lu, X.; Seidel, D.; Zander, T.; Leenders, F.; Ozretić, L.; Brustugun, O.-T.; Field, J.K.; Wright, G.; et al. Abstract 1531: Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets. Cancer Res. 2014, 74 (Suppl. 19), 1531. [Google Scholar] [CrossRef]
- Lin, G.; Liu, Y.; Li, H.; Chen, S.; Guo, Y. Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation. Clin. Lung Cancer 2021, 22, e712–e715. [Google Scholar] [CrossRef]
- Stang, A.; Becker, J.C.; Nghiem, P.; Ferlay, J. The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment. Eur. J. Cancer 2018, 94, 47–60. [Google Scholar] [CrossRef]
- Garrett, G.L.; Blanc, P.D.; Boscardin, J.; Lloyd, A.A.; Ahmed, R.L.; Anthony, T.; Bibee, K.; Breithaupt, A.; Cannon, J.; Chen, A.; et al. Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. JAMA Dermatol. 2017, 153, 296–303. [Google Scholar] [CrossRef]
- Harms, P.W.; Harms, K.L.; Moore, P.S.; DeCaprio, J.A.; Nghiem, P.; Wong, M.K.K.; Brownell, I.; the International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group. The biology and treatment of Merkel cell carcinoma: Current understanding and research priorities. Nat. Rev. Clin. Oncol. 2018, 15, 763–776. [Google Scholar] [CrossRef] [Green Version]
- Lebbe, C.; Becker, J.C.; Grob, J.J.; Malvehy, J.; Del Marmol, V.; Pehamberger, H.; Peris, K.; Saiag, P.; Middleton, M.R.; Bastholt, L.; et al. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur. J. Cancer 2015, 51, 2396–2403. [Google Scholar] [CrossRef] [PubMed]
- Hechtman, J.F. NTRK insights: Best practices for pathologists. Mod. Pathol. 2022, 35, 298–305. [Google Scholar] [CrossRef] [PubMed]
- Rosen, E.Y.; Goldman, D.A.; Hechtman, J.F.; Benayed, R.; Schram, A.M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J.P.; et al. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clin. Cancer Res. 2020, 26, 1624–1632. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vaishnavi, A.; Capelletti, M.; Le, A.T.; Kako, S.; Butaney, M.; Ercan, D.; Mahale, S.; Davies, K.D.; Aisner, D.L.; Pilling, A.B.; et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat. Med. 2013, 19, 1469–1472. [Google Scholar] [CrossRef] [Green Version]
- Benayed, R.; Offin, M.; Mullaney, K.; Sukhadia, P.; Rios, K.; Desmeules, P.; Ptashkin, R.; Won, H.; Chang, J.; Halpenny, D.; et al. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clin. Cancer Res. 2019, 25, 4712–4722. [Google Scholar] [CrossRef]
- Harrison, B.T.; Fowler, E.; Krings, G.; Chen, Y.Y.; Bean, G.R.; Vincent-Salomon, A.; Fuhrmann, L.; Barnick, S.E.; Chen, B.; Hosfield, E.M.; et al. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast. Am. J. Surg. Pathol. 2019, 43, 1693–1700. [Google Scholar] [CrossRef]
- Hung, Y.P.; Jo, V.Y.; Hornick, J.L. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma. Histopathology 2019, 75, 54–62. [Google Scholar] [CrossRef]
- Cappellesso, R.; Nozzoli, F.; Zito Marino, F.; Simi, S.; Castiglione, F.; De Giorgi, V.; Cota, C.; Senetta, R.; Scognamiglio, G.; Anniciello, A.M.; et al. NTRK Gene Fusion Detection in Atypical Spitz Tumors. Int. J. Mol. Sci. 2021, 22, 12332. [Google Scholar] [CrossRef]
- Jenkins, B.A.; Lumpkin, E.A. Developing a sense of touch. Development 2017, 144, 4078–4090. [Google Scholar] [CrossRef]
- Cronk, K.M.; Wilkinson, G.A.; Grimes, R.; Wheeler, E.F.; Jhaveri, S.; Fundin, B.T.; Silos-Santiago, I.; Tessarollo, L.; Reichardt, L.F.; Rice, F.L. Diverse dependencies of developing Merkel innervation on the trkA and both full-length and truncated isoforms of trkC. Development 2002, 129, 3739–3750. [Google Scholar] [CrossRef] [PubMed]
- Harms, P.W.; Vats, P.; Verhaegen, M.E.; Robinson, D.R.; Wu, Y.M.; Dhanasekaran, S.M.; Palanisamy, N.; Siddiqui, J.; Cao, X.; Su, F.; et al. The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Res. 2015, 75, 3720–3727. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goh, G.; Walradt, T.; Markarov, V.; Blom, A.; Riaz, N.; Doumani, R.; Stafstrom, K.; Moshiri, A.; Yelistratova, L.; Levinsohn, J.; et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 2016, 7, 3403–3415. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, S.Q.; Waldeck, K.; Vergara, I.A.; Schröder, J.; Madore, J.; Wilmott, J.S.; Colebatch, A.J.; De Paoli-Iseppi, R.; Li, J.; Lupat, R.; et al. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Res. 2015, 75, 5228–5234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elder, D.E.; Massi, D.; Scolyer, R.A.; Willemze, R.; World Health Organization. WHO Classification of Skin Tumours; International Agency for Research on Cancer: Lyon, France, 2018. [Google Scholar]
- Goh, S.; Lindau, C.; Tiveljung-Lindell, A.; Allander, T. Merkel cell polyomavirus in respiratory tract secretions. Emerg. Infect. Dis. 2009, 15, 489–491. [Google Scholar] [CrossRef]
- Schowalter, R.M.; Pastrana, D.V.; Pumphrey, K.A.; Moyer, A.L.; Buck, C.B. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe 2010, 7, 509–515. [Google Scholar] [CrossRef]
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2020; Available online: https://www.R-project.org/ (accessed on 4 December 2022).
Category | n | % |
---|---|---|
Age at diagnosis (yrs) | ||
- Mean (SD) - Range | 72.2 (11.5) 45–95 | |
Gender | ||
- Male - Female | 36 40 | 47 53 |
Primary site | ||
- Eyelid - Head and neck - Trunk - Extremity | 3 20 8 45 | 4 26 11 59 |
MCPyV | ||
- Positive - Negative | 43 33 | 57 43 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cappellesso, R.; Nicolè, L.; Del Fiore, P.; Barzon, L.; Sinigaglia, A.; Riccetti, S.; Franco, R.; Zito Marino, F.; Munari, G.; Zamuner, C.; et al. TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions. Int. J. Mol. Sci. 2022, 23, 15366. https://doi.org/10.3390/ijms232315366
Cappellesso R, Nicolè L, Del Fiore P, Barzon L, Sinigaglia A, Riccetti S, Franco R, Zito Marino F, Munari G, Zamuner C, et al. TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions. International Journal of Molecular Sciences. 2022; 23(23):15366. https://doi.org/10.3390/ijms232315366
Chicago/Turabian StyleCappellesso, Rocco, Lorenzo Nicolè, Paolo Del Fiore, Luisa Barzon, Alessandro Sinigaglia, Silvia Riccetti, Renato Franco, Federica Zito Marino, Giada Munari, Carolina Zamuner, and et al. 2022. "TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions" International Journal of Molecular Sciences 23, no. 23: 15366. https://doi.org/10.3390/ijms232315366